Associate Professor Judith Trotman

Clinical Professor
Medicine, Concord Clinical School

Telephone +61 2 9767 7243
Fax +61 2 9767 7650

Map

Biographical details

Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is a Senior Staff Specialist and Director of the Clinical Research Unit in the Haematology Department, Concord Hospital.

Trained in Auckland and Sydney she has a particular interest in lymphoma care. She established the Clinical Research Unit at Concord Hospital where she has built a broad portfolio of trials across the spectrum of lymphoid malignancies, not just delivering "World class care, locally" but accessing emerging new therapies for patients from across NSW.

Dr Trotman worked as a scholar and clinician in 2009-2010 in the Clinical Research Unit in Hôpital Lyon-Sud, France, within LYSA, the world leading French lymphoma trials collaborative. Her own research demonstrating the predictive power of PET-CT response assessment after first-line therapy in PRIMA, the world's largest clinical trial in Follicular Lymphoma,impacted on NCCN guidelines and was published in the Journal of Clinical Oncology 2011, then as Principal Investigator in the international FOLLCOLL study she conducted a pooled analysis of PET in three large trials, published in Lancet Haematology in 2014. It was her work on postinduction PET in the GALLIUM study that firmly established PET as the gold standard response assessment modality in Follicular Lymphoma. On the basis of her data she successfully secured MBS funding for PET in indolent lymphoma.

Committed to both Australian based research and international collaborations she is a member of the ALLG (Australian Leukaemia and Lymphoma Group) Scientific Advisory Committee and the Chair of the Low Grade Lymphoma Committee, and Principal Investigator for two international studies: the UK-led, NHMRC funded, Response Adapted Therapy in Hodgkin Lymphoma study, (Johnson P, NEJM 2016) and the French-led, REMARC-NHL25 study of Lenalidomide maintenance for older patients with diffuse large B cell lymphoma (Thieblemont C, JCO 2017). and of RePLy an ALLG world-first study of PET-adapted therapy for patients with relapsed Follicular Lymphoma, and IRiC a novel study of Ibrutinib plus mini-RCHOP in very elderly patients with DLBCL.She is co-principal investigator on the Waldenstrom’s Macroglobulinaemia Study Involving CART-WHEEL,(WhiMSICAL), an innovative research partnership with patient investigators from the International WM Foundation (IWMF). She is supervising the development of another smartphone App "My Hodgkin's, My Health" for long term follow-up of patients with Hodgkin Lymphoma. Other national research collaborations include the pharmacokinetics of High Dose Melphalan, the chemotherapy conditioning regimen used before autologous transplantation in Myeloma, (Trotman J, Br J Pharm 2016).

She is coinventor of ClinTrial Refer, a smartphone and tablet App that has facilitated increased collaboration in cross-referral and recruitment to clinical trials across 18 research portfolios internationally.

She has published extensively in leading journals including NEJM, Blood, Lancet, Lancet Oncology, Journal of Clinical Oncology and The Lancet Haematology. Awarded Best Lecturer Year 1 at Concord 2015 she has supervised Honours and MD student theses. Dr Trotman serves on the Board of the Australian Clinical Trials Alliance, (ACTA).

Research interests

Lymphoproliferative diseases.

Myeloma

Multidisciplinary care

Teaching and supervision

Since 2003 A/Prof Trotman has been a tutor, lecturer and the coordinator of the Stage I, Haematology Block, in the Sydney Medical Program. This five week program provides Concord medical students with their first full-time exposure to learning in the Hospital environment. The shared commitment by her and her Concord Haematology colleagues to this program is evidenced by excellent student feedback and performance in RFAs. She is also extensively involved in post graduate teaching for both RACP and RCPA trainees. For 18 years she has been an invited lecturer in haematologic malignancies at the Aljessal/RPAH course for basic physician trainees. She is active in patient education, hosting leading international colleagues at several myeloma and lymphoma patient education fora held inthe Concord medical centre, including Australia's first ever patient education session in Italian.

Awards and honours

2018 Snowdome Foundation $150,000 forPETReA ALLG NHL30 study.

2017 MTP Connect, Department of Innovation Industry and Sceince: PRJ2017-47, $375,000 Grant plus $375,000 matched Industry funding for ClinTrial Refer Australia

2016 Drummoyne Local Woman of the Year.

2016 $40,000 from Sydney Health Partners for the development of a SHP ClinTrial Refer App.

2016 $20,000to Biogrid Australia from Janssen for the WhiMSICAL project. This study utilises CART-WHEEL, a global, online rare cancer database for patient-derived data, to gain a real-world understanding of WM.

2014 NHMRC APP1058993 Blood Biomarkers in Hodgkin Lymphoma. CIA Prof Maher Gandhi. CIC. $513,000

2014 Cancer Institute NSW Research Equipment Grant 14/REG/1-03, “A UPLC QTOF to improve cancer treatment and outcomes”. Nath CE, Shaw P, Trotman J, Larsen S, Gurney H, Byrne J, Haber M, Norris M, Marshall G, Munns C. AUD $91,959.

2015- ALLG NHL28 IRiC Study of Ibrutinib-mini-R-CHOP in very elderly DLBCL. Janssen Pharmaceutical International ($0,000,000 confidential) IIS funding approval for an ALLG Phase II 80 patient study.
I mentor my Co-Principal investigator Dr Emma Verner.

2012-2015ALLG NHL26 RePLY: PET in Follicular Lymphoma study

In April 2012 I secured funding support from Celgene International to the ALLG for $000,000 (confidential) plus ~ $1M study drug to support an ALLG sponsored clinical trial of PET adapted Lenalidomide consolidation therapy for 80 patients with relapsed follicular lymphoma.

2011-2013 ALLG Study NHL25 REMARC

As ALLG Principal Investigator I secured GELA (Groupe d’Etudes de Lymphomes d’Adultes) funding ($000,000 confidential) for the ALLG sponsorship to participate in REMARC:A Phase III study of Lenalidomide (Revlimid) maintenance vs. placebo in responding elderly patients with Diffuse Large B cell Lymphoma treated with R-CHOP.

2006-09 NHMRC Project grant #396702, $466,000.

Chief Investigator C on the Melphalan Pharmacokinetics in Myeloma Transplant project with CIA, Dr Christa Nath, Pharmacokineticist, and CIB A/Prof Peter Shaw, Children’s Hospital at Westmead.

2010-2013 ALLG HD8: RATHL Study: Cancer Australia Priority driven Cancer Collaborative Research Grant #628610, $340,000 Securing funding from the DoHA /Cancer Australia /Leukaemia Foundation for this ALLG study of PET-adapted therapy in Hodgkin Lymphoma.

2005 - currentNSW Cancer Institute:

  • Clinical Research Coordinator Grant $90,000 p.a., Jan 2012- Dec 2018

  • Chief Investigator for SLHD 2013-2015 Grant 11/CTS 2-05

Funding for six clinical trial coordinators across NSW with excellent recruitment achieved.

  • Clinical Trials Establishment Grant, 05EST 1-08. $90,000 p.a. 2005-2011

Having successfully lobbied for the existence of “Establishment Grants” for new Clinical Trials Units, I secured one for Concord Haematology.

  • Clinical Study Grant 2009/INS/2-03 $14,492.

This International Study Grant provided support for my otherwise self-funded year’s lymphoma research sabbatical in France.

  • NSW Cancer Council Clinical Trials Grant, 2006 - 2011

Shared 0.5FTE ($30,000 p.a.) grant with Oncology, A/Prof P Beale.

In the media

2018 Featured Doctor in DocStar Article in the April Edition for The Torch, the quarterly newsletter of the International Waldenstroms Macroglobulinaemia Foundation (IWMF).

2017 Media interview: Dr Norman Swan The Health Report. National Radio.
http://radio.abc.net.au/programitem/pgx7LKngAV?play=true

A revolution in lymphoma treatment on Health Report - ABC Radio. MBS Listing of PET in FL

2017 I ventured into Twitter in 2017 – posting and responding to commentary on lymphoma literature and gender equity in STEM. I have 410 twitter followers.

2017 Interview SBS Radio re. A Bloody Great Night Out Sept 24

2017- Member, Scientific Advisory Board, LymphomaHub

2017 Interview at ASH 2017 by LymphomaHub re. BRIGHT study and impact on my clinical practice

2017 Member of The Bloody Great Committee organising A Bloody Great Night Out! raising $161,000 from 660 attendees, including 4 local politicians at Le Montage 15 Sept. This bi-annual event also raises the profile of our world-leading clinical research and of CRGH as an academic hospital.

Total CRU fundraising for 2017 ~$300,000

Keywords

Haematology

Clinical Specialty

Haematology

International links

France

(Hospices Civils de Lyon/Université de Lyon, Pierre-Bénite, France) PET and Lymphoma collaboration

Italy

(Oncologia Medica II Università di Modena e Reggio Emilia COM - Centro Oncologico Modenese Via del Pozzo 71 41124 Modena ) Lymphoma collaboration

United Kingdom

(Sally F Barrington Reader in Nuclear Medicine PET Imaging Centre at St Thomas' Lambeth Palace Road London SE1 7EH ) Collaboration in PET in Lymphoma projects

United Kingdom

(University of Southhampton) Hodgkin Lymphoma collaboration with the UKNCRI

Selected grants

2006

  • Using melphalan blood concentrations to reduce toxicity and improve transplant outcome in adult myel; Trotman J, Nath C, Shaw P, Kerridge I; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gopal, A., Schuster, S., Fowler, N., Trotman, J., Hess, G., Hou, J., Yacoub, A., Lill, M., Martin, P., Vitolo, U., et al (2018). Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Journal of Clinical Oncology, 36(23), 2405-2412. [More Information]
  • Hiddemann, W., Barbui, A., Canales, M., Cannell, P., Collins, G., Durig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., Trotman, J., et al (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology, 36(23), 2395-2406. [More Information]
  • Dimopoulos, M., Tedeschi, A., Trotman, J., Garcia-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., et al (2018). Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. New England Journal of Medicine, 378(25), 2399-2410. [More Information]
  • Cottereau, A., Versari, A., Luminari, S., Dupuis, J., Chartier, L., Casasnovas, R., Berriolo-Riedinger, A., Menga, M., Haioun, C., Tilly, H., Trotman, J., et al (2018). Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study. Blood, 131(22), 2449-2453. [More Information]
  • Othman, J., Verner, E., Tam, C., Huang, J., Lin, L., Hilger, J., Trotman, J., Gasiorowski, R. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. Haematologica, 103(5), e223-e225. [More Information]
  • Prince, H., Kim, Y., Horwitz, S., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P., Wolter, P., Sanches, J., Trotman, J., et al (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet, 390(10094), 555-566. [More Information]
  • Hertzberg, M., Gandhi, M., Trotman, J., Butcher, B., Taper, J., Johnston, A., Gill, D., Ho, S., Cull, G., Fay, K., et al (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102(2), 356-363. [More Information]
  • Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]
  • Dimopoulos, M., Trotman, J., Tedeschi, A., Matous, J., Macdonald, D., Tam, C., Tournilhac, O., Ma, S., Oriol, A., Heffner, L., et al (2017). Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology, 18(2), 241-250. [More Information]
  • Thieblemont, C., Tilly, H., Gomes da Silva, M., Casasnovas, R., Fruchart, C., Morschhauser, F., Haioun, C., Lazarovici, J., Grosicka, A., Trotman, J., et al (2017). Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 35(22), 2473-2481. [More Information]
  • Meignan, M., Cottereau, A., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R., Haioun, C., Trotman, J., et al (2017). Reply to HJA Adams et al and E Laffon et al. Journal of Clinical Oncology, 35(8), 920-922. [More Information]
  • Nanni, C., Cottereau, A., Lopci, E., Bodet-Milin, C., Coronado, M., Pro, B., Kim, W., Trotman, J., Barrington, S., Duhrsen, U., et al (2017). Report of the 6th International Workshop on PET in lymphoma. Leukemia & Lymphoma, 58(10), 2298-2303. [More Information]
  • Federico, M., Trotman, J., Dreyling, M. (2017). Time to publish: challenging the performance of cooperative group lymphoma trials. The Lancet Haematology, 4(1), e8-e10. [More Information]
  • Talaulikar, D., Tam, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Gibson, J., Trotman, J., Ward, C., et al (2017). Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47(1), 35-49. [More Information]
  • Quach, H., Fernyhough, L., Henderson, R., Corbett, G., Baker, B., Browett, P., Blacklock, H., Forsyth, C., Underhill, C., Cannell, P., et al (2017). Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British Journal of Haematology, 177(3), 441-448. [More Information]
  • Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., D'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., Trotman, J., et al (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. New England Journal of Medicine, 374(25), 2419-2429. [More Information]
  • Meignan, M., Cottereau, A., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R., Haioun, C., Trotman, J., et al (2016). Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. Journal of Clinical Oncology, 34(30), 3618-3626. [More Information]
  • Nath, C., Trotman, J., Tiley, C., Presgrave, P., Joshua, D., Kerridge, I., Kwan, Y., Gurney, H., McLachlan, A., Earl, J., Shaw, P., et al (2016). High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 82(1), 149-159. [More Information]
  • Barrington, S., Kirkwood, A., Franceschetto, A., Fulham, M., Roberts, T., Almquist, H., Brun, E., Hjorthaug, K., Viney, Z., Pike, L., Trotman, J., et al (2016). PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 127(12), 1531-1538. [More Information]
  • Millar, A., Ellis, M., Mollee, P., Cochrane, T., Fletcher, J., Caudron, A., Webster, B., Trotman, J. (2015). Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with Diffuse Large B Cell Lymphoma: an Australian retrospective analysis. Internal Medicine Journal, 45(11), 1147-1153. [More Information]
  • Moran, N., Webster, B., Lee, K., Trotman, J., Kwan, Y., Napoli, J., Leong, R. (2015). Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World Journal of Gastroenterology, 21(19), 6072-6076. [More Information]
  • Luminari, S., Trotman, J. (2015). Positron emission tomography-computed tomography in follicular lymphoma: "One fit for all"? Leukemia and Lymphoma, 56(5), 1191-1192. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 33(10), 1221-1223. [More Information]
  • Barrington, S., Mikhael, N., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to G. Keramida et al. Journal of Clinical Oncology, 38(34), 4121-4122. [More Information]
  • Yeung, D., Osborn, M., White, D., Braley, J., Herschtal, A., Branford, S., Kornhauser, M., Issa, S., Hiwase, D., Hertzberg, M., Trotman, J., Taper, J., et al (2015). TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. [More Information]
  • Tychyj-Pinel, C., Ricard, F., Fulham, M., Fournier, M., Meignan, M., Lamy, T., Vera, P., Salles, G., Trotman, J. (2014). PET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study. European Journal of Nuclear Medicine and Molecular Imaging, 41(3), 408-415. [More Information]
  • Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj-Pinel, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al (2014). Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet Haematology, 1(1), e17-e27. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Robledo, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2014). Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048-3058. [More Information]
  • Seymour, J., Trotman, J., Hofman, M. (2013). Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 54(10), 2093-2095. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
  • Trotman, J., Fournier, M., Lamy, T., Seymour, J., Sonet, A., Janíkova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Fulham, M., et al (2011). Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 29(23), 3194-3200. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Michallet, A., Trotman, J., Tychyj-Pinel, C. (2010). Role of early PET in the management of diffuse large B-cell lymphoma. Current Opinion in Oncology, 22(5), 414-8. [More Information]
  • Nath, C., Zeng, L., Eslick, A., Trotman, J., Earl, J. (2008). An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatographicae, 20(3), 383-398. [More Information]
  • Trotman, J., Presgrave, P., Kwan, Y., Tiley, C., Estell, J., Watson, A., O'Brien, T., Peters, D. (2008). Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales. Internal Medicine Journal, 38(4), 229-234. [More Information]
  • Chung, T., Lim, W., Sy, R., Cunningham, I., Trotman, J., Kritharides, L. (2008). Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart, 94(7), 911-918. [More Information]

2018

  • Gopal, A., Schuster, S., Fowler, N., Trotman, J., Hess, G., Hou, J., Yacoub, A., Lill, M., Martin, P., Vitolo, U., et al (2018). Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Journal of Clinical Oncology, 36(23), 2405-2412. [More Information]
  • Hiddemann, W., Barbui, A., Canales, M., Cannell, P., Collins, G., Durig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., Trotman, J., et al (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology, 36(23), 2395-2406. [More Information]
  • Dimopoulos, M., Tedeschi, A., Trotman, J., Garcia-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., et al (2018). Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. New England Journal of Medicine, 378(25), 2399-2410. [More Information]
  • Cottereau, A., Versari, A., Luminari, S., Dupuis, J., Chartier, L., Casasnovas, R., Berriolo-Riedinger, A., Menga, M., Haioun, C., Tilly, H., Trotman, J., et al (2018). Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study. Blood, 131(22), 2449-2453. [More Information]
  • Othman, J., Verner, E., Tam, C., Huang, J., Lin, L., Hilger, J., Trotman, J., Gasiorowski, R. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. Haematologica, 103(5), e223-e225. [More Information]

2017

  • Prince, H., Kim, Y., Horwitz, S., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P., Wolter, P., Sanches, J., Trotman, J., et al (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet, 390(10094), 555-566. [More Information]
  • Hertzberg, M., Gandhi, M., Trotman, J., Butcher, B., Taper, J., Johnston, A., Gill, D., Ho, S., Cull, G., Fay, K., et al (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102(2), 356-363. [More Information]
  • Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]
  • Dimopoulos, M., Trotman, J., Tedeschi, A., Matous, J., Macdonald, D., Tam, C., Tournilhac, O., Ma, S., Oriol, A., Heffner, L., et al (2017). Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology, 18(2), 241-250. [More Information]
  • Thieblemont, C., Tilly, H., Gomes da Silva, M., Casasnovas, R., Fruchart, C., Morschhauser, F., Haioun, C., Lazarovici, J., Grosicka, A., Trotman, J., et al (2017). Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 35(22), 2473-2481. [More Information]
  • Meignan, M., Cottereau, A., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R., Haioun, C., Trotman, J., et al (2017). Reply to HJA Adams et al and E Laffon et al. Journal of Clinical Oncology, 35(8), 920-922. [More Information]
  • Nanni, C., Cottereau, A., Lopci, E., Bodet-Milin, C., Coronado, M., Pro, B., Kim, W., Trotman, J., Barrington, S., Duhrsen, U., et al (2017). Report of the 6th International Workshop on PET in lymphoma. Leukemia & Lymphoma, 58(10), 2298-2303. [More Information]
  • Federico, M., Trotman, J., Dreyling, M. (2017). Time to publish: challenging the performance of cooperative group lymphoma trials. The Lancet Haematology, 4(1), e8-e10. [More Information]
  • Talaulikar, D., Tam, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Gibson, J., Trotman, J., Ward, C., et al (2017). Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47(1), 35-49. [More Information]
  • Quach, H., Fernyhough, L., Henderson, R., Corbett, G., Baker, B., Browett, P., Blacklock, H., Forsyth, C., Underhill, C., Cannell, P., et al (2017). Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British Journal of Haematology, 177(3), 441-448. [More Information]

2016

  • Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., D'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., Trotman, J., et al (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. New England Journal of Medicine, 374(25), 2419-2429. [More Information]
  • Meignan, M., Cottereau, A., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R., Haioun, C., Trotman, J., et al (2016). Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. Journal of Clinical Oncology, 34(30), 3618-3626. [More Information]
  • Nath, C., Trotman, J., Tiley, C., Presgrave, P., Joshua, D., Kerridge, I., Kwan, Y., Gurney, H., McLachlan, A., Earl, J., Shaw, P., et al (2016). High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 82(1), 149-159. [More Information]
  • Barrington, S., Kirkwood, A., Franceschetto, A., Fulham, M., Roberts, T., Almquist, H., Brun, E., Hjorthaug, K., Viney, Z., Pike, L., Trotman, J., et al (2016). PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 127(12), 1531-1538. [More Information]

2015

  • Millar, A., Ellis, M., Mollee, P., Cochrane, T., Fletcher, J., Caudron, A., Webster, B., Trotman, J. (2015). Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with Diffuse Large B Cell Lymphoma: an Australian retrospective analysis. Internal Medicine Journal, 45(11), 1147-1153. [More Information]
  • Moran, N., Webster, B., Lee, K., Trotman, J., Kwan, Y., Napoli, J., Leong, R. (2015). Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World Journal of Gastroenterology, 21(19), 6072-6076. [More Information]
  • Luminari, S., Trotman, J. (2015). Positron emission tomography-computed tomography in follicular lymphoma: "One fit for all"? Leukemia and Lymphoma, 56(5), 1191-1192. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 33(10), 1221-1223. [More Information]
  • Barrington, S., Mikhael, N., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to G. Keramida et al. Journal of Clinical Oncology, 38(34), 4121-4122. [More Information]
  • Yeung, D., Osborn, M., White, D., Braley, J., Herschtal, A., Branford, S., Kornhauser, M., Issa, S., Hiwase, D., Hertzberg, M., Trotman, J., Taper, J., et al (2015). TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. [More Information]

2014

  • Tychyj-Pinel, C., Ricard, F., Fulham, M., Fournier, M., Meignan, M., Lamy, T., Vera, P., Salles, G., Trotman, J. (2014). PET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study. European Journal of Nuclear Medicine and Molecular Imaging, 41(3), 408-415. [More Information]
  • Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj-Pinel, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al (2014). Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet Haematology, 1(1), e17-e27. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Robledo, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2014). Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048-3058. [More Information]

2013

  • Seymour, J., Trotman, J., Hofman, M. (2013). Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 54(10), 2093-2095. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]

2011

  • Trotman, J., Fournier, M., Lamy, T., Seymour, J., Sonet, A., Janíkova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Fulham, M., et al (2011). Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 29(23), 3194-3200. [More Information]

2010

  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Michallet, A., Trotman, J., Tychyj-Pinel, C. (2010). Role of early PET in the management of diffuse large B-cell lymphoma. Current Opinion in Oncology, 22(5), 414-8. [More Information]

2008

  • Nath, C., Zeng, L., Eslick, A., Trotman, J., Earl, J. (2008). An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatographicae, 20(3), 383-398. [More Information]
  • Trotman, J., Presgrave, P., Kwan, Y., Tiley, C., Estell, J., Watson, A., O'Brien, T., Peters, D. (2008). Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales. Internal Medicine Journal, 38(4), 229-234. [More Information]
  • Chung, T., Lim, W., Sy, R., Cunningham, I., Trotman, J., Kritharides, L. (2008). Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart, 94(7), 911-918. [More Information]

To update your profile click here. For support on your academic profile contact .